People at 'intermediate risk' of heart disease with elevated hsCRP benefit from statin therapy

Women and men with a 10-year cardiovascular disease risk of 5 percent or more and normal cholesterol levels but high levels of hsCRP, a protein associated with inflammation, could reduce their risk substantially with statin therapy, according to new research.

Read the whole article on Physorg

More from Physorg